Using genetic markers to predict prostate cancer outcomes
Official title: Predicting prostate cancer clinical outcomes with germline genomic biomarkers
Funded at University of California Los Angeles · NIH-11080750 · Data updated 2026-11-12
This study is looking at how your genes might help doctors understand the likely outcomes of prostate cancer, so they can better tell if it’s a slow-growing or aggressive type, which could lead to more personalized treatment options for men facing this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $41,892 |
| NIH project number | 5F31CA281168-02 |
| Project ID | NIH-11080750 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include American men diagnosed with localized prostate cancer, particularly those with a family history of the disease.
✕Less likely to help
Patients with advanced prostate cancer or those who do not have a genetic predisposition to the disease may not benefit from this research.
What this research studies
This research investigates how genetic factors can help predict the clinical outcomes of prostate cancer in men. It aims to improve the accuracy of risk assessments by examining hereditary factors, particularly focusing on DNA damage repair genes and genetic ancestry. By identifying specific genetic markers, the study seeks to differentiate between indolent and aggressive forms of localized prostate cancer, potentially leading to better treatment decisions for patients. The research will involve analyzing patient data and genetic information to enhance current clinical practices.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of prostate cancer progression, allowing for personalized treatment plans and reducing unnecessary overtreatment.
How similar studies have gone: Previous research has shown promise in using genetic markers for cancer prognosis, indicating that this approach could lead to significant advancements in prostate cancer management.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Zeltser, Nicole — University of California Los Angeles
- Study coordinator: Zeltser, Nicole
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.